Clinical Trial Update: BKM120+Abiraterone Acetate for Metastatic CRPC [Phase 1]

View source ↗

Summary

Phase 1 study of Buparlisib (BKM120) in combination with Abiraterone acetate for metastatic castration-resistant prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Buparlisib (BKM120) (buparlisib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED